8-K

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D. C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) ofthe

Securities Exchange Act of 1934

February 18, 2022

Date of Report (Date of earliest event reported)

ABBOTT LABORATORIES

(Exact name of registrant as specified in charter)

100 Abbott Park Road

Abbott Park, Illinois 60064-6400

(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code:

(224) 667-6100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨        Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨        Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨        Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨        Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered Pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

On February 17, 2022, Abbott initiated a proactive, voluntary recall of Similac-brand powder infant formulas manufactured in Sturgis, Michigan.  The recall primarily involves product distributed in the U.S. and Canada.  Abbott is confirming its previously issued full-year 2022 guidance for adjusted diluted earnings per share from continuing operations of at least $4.70.  Abbott will incur a one-time specified item in the first quarter 2022 for recall related expenses, including inventory destruction and other recall expenses.  These expenses have not yet been quantified.  However, Abbott does not expect that these expenses will have a material impact on Abbott’s consolidated financial statements.  Abbott has issued a press release informing consumers.

The information contained in this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in any such filing.

— Private Securities Litigation ReformAct of 1995 —

A Caution Concerning Forward-Looking Statements

Some statements in this Current Report may be forward-looking statementsfor purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subjectto risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements.Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "RiskFactors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2020, and are incorporated herein by reference.Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments,except as required by law.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.